AR118750A1 - UN PROCESO PARA PREPARAR UNA FORMA CRISTALINA DE 2-(3-(4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-1-(CICLOPROPILSULFONILO)AZETIDIN-3-IL)ACETONITRILO QUE POSEE ACTIVIDAD INHIBIDORA DE JAK - Google Patents

UN PROCESO PARA PREPARAR UNA FORMA CRISTALINA DE 2-(3-(4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-1-(CICLOPROPILSULFONILO)AZETIDIN-3-IL)ACETONITRILO QUE POSEE ACTIVIDAD INHIBIDORA DE JAK

Info

Publication number
AR118750A1
AR118750A1 ARP200101129A ARP200101129A AR118750A1 AR 118750 A1 AR118750 A1 AR 118750A1 AR P200101129 A ARP200101129 A AR P200101129A AR P200101129 A ARP200101129 A AR P200101129A AR 118750 A1 AR118750 A1 AR 118750A1
Authority
AR
Argentina
Prior art keywords
cyclopropylsulfonyl
azetidin
pyrimidin
acetonitrile
crystalline form
Prior art date
Application number
ARP200101129A
Other languages
English (en)
Inventor
Timothy Andrew Woods
Jingdan Hu
Original Assignee
Elanco Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elanco Us Inc filed Critical Elanco Us Inc
Publication of AR118750A1 publication Critical patent/AR118750A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente descripción proporciona un método para preparar una forma cristalina de 2-(3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-1-(ciclopropilsulfonil)azetidin-3-il)acetonitrilo y su utilización en el tratamiento de afecciones dermatológicas tales como dermatitis atópica y prurito. Reivindicación 1: Un proceso para preparar 2-(3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-1-(ciclopropilsulfonilo)azetidin-3-il)acetonitrilo cristalino sustancialmente polimórficamente puro caracterizado por el patrón de difracción de rayos X en polvo que comprende un pico a 5,34º, 10,68º, 14,26º, 16,06º, 16,39º, 16,48º, 18,26º, 18,65º, 21,05º, 21,76º, 22,68º, o 26,75º (± 0,2º 2q), cuyo proceso comprende la cristalización de un solvente seleccionado del grupo que consiste en un alcohol C₁₋₅, un alquiléter C₂₋₈, un acetato de alquilo C₂₋₈, un cianuro de alquilo C₂₋₅, una alquilcetona C₃₋₉ y un solvente aromático, o una mezcla de los mismos; en donde el solvente o la mezcla de solventes tienen una actividad de agua de menos de 0,7.
ARP200101129A 2019-04-24 2020-04-22 UN PROCESO PARA PREPARAR UNA FORMA CRISTALINA DE 2-(3-(4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-1-(CICLOPROPILSULFONILO)AZETIDIN-3-IL)ACETONITRILO QUE POSEE ACTIVIDAD INHIBIDORA DE JAK AR118750A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962837972P 2019-04-24 2019-04-24

Publications (1)

Publication Number Publication Date
AR118750A1 true AR118750A1 (es) 2021-10-27

Family

ID=70614675

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101129A AR118750A1 (es) 2019-04-24 2020-04-22 UN PROCESO PARA PREPARAR UNA FORMA CRISTALINA DE 2-(3-(4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-1-(CICLOPROPILSULFONILO)AZETIDIN-3-IL)ACETONITRILO QUE POSEE ACTIVIDAD INHIBIDORA DE JAK

Country Status (11)

Country Link
US (2) US11548895B2 (es)
EP (1) EP3958968A1 (es)
JP (2) JP7241916B2 (es)
KR (1) KR20210141634A (es)
CN (1) CN114466681A (es)
AR (1) AR118750A1 (es)
AU (2) AU2020262100B2 (es)
BR (1) BR112021020508A2 (es)
CA (1) CA3134750A1 (es)
MX (1) MX2021012849A (es)
WO (1) WO2020219524A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3958968A1 (en) 2019-04-24 2022-03-02 Elanco Us Inc. A 7h-pyrrolo[2,3-d]pyrimidine jak-inhibitor
US20230404925A1 (en) * 2020-10-23 2023-12-21 Elanco Us Inc. Jak inhibitors having a specific particle size distribution
CA3201608A1 (en) 2020-12-18 2022-06-23 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof
AU2022331122A1 (en) 2021-08-20 2024-02-15 Intervet International B.V. Homodimer fusion proteins for treating atopic dermatitis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE030235T2 (en) 2005-12-13 2017-04-28 Incyte Holdings Corp Heteroaryl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors
ES2602577T3 (es) * 2008-03-11 2017-02-21 Incyte Holdings Corporation Derivados de azetidina y ciclobutano como inhibidores de JAK
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
WO2016141891A1 (zh) 2015-03-11 2016-09-15 苏州晶云药物科技有限公司 Jak抑制剂的晶型及其制备方法
AR104918A1 (es) 2015-06-19 2017-08-23 Lilly Co Eli Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo
WO2019003249A1 (en) * 2017-06-28 2019-01-03 Mylan Laboratories Limited POLYMORPHIC FORMS OF BARICITINIB
EP3958968A1 (en) 2019-04-24 2022-03-02 Elanco Us Inc. A 7h-pyrrolo[2,3-d]pyrimidine jak-inhibitor

Also Published As

Publication number Publication date
EP3958968A1 (en) 2022-03-02
US20200339585A1 (en) 2020-10-29
JP7241916B2 (ja) 2023-03-17
JP2023071922A (ja) 2023-05-23
BR112021020508A2 (pt) 2021-12-07
US11548895B2 (en) 2023-01-10
US20230056365A1 (en) 2023-02-23
WO2020219524A1 (en) 2020-10-29
KR20210141634A (ko) 2021-11-23
MX2021012849A (es) 2022-02-24
JP2022530441A (ja) 2022-06-29
AU2020262100A1 (en) 2021-11-11
AU2023203627A1 (en) 2023-07-06
CN114466681A (zh) 2022-05-10
CA3134750A1 (en) 2020-10-29
AU2020262100B2 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
AR118750A1 (es) UN PROCESO PARA PREPARAR UNA FORMA CRISTALINA DE 2-(3-(4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-1-(CICLOPROPILSULFONILO)AZETIDIN-3-IL)ACETONITRILO QUE POSEE ACTIVIDAD INHIBIDORA DE JAK
ES2674174T3 (es) Antagonista de LPA1 policíclico y usos del mismo
MX2019011785A (es) Proceso para preparar compuestos de 2,3-dihidrotiazolo[3,2-a]pirim idin-4-io quirales.
MX340124B (es) Anticuerpos biespecificos.
CA2922933C (en) 2,8-diazaspiro[4.5]decane and 3,9-dispiro[5.5]undecane derivates and pharmaceutical compositions thereof useful as tryptophan hydroxylase inhibitors
BR112017013382A2 (pt) método para preparar um composto, composto, e, ácido.
CO6630189A2 (es) Compuestos heterocíclicos de nitrógeno útiles como inhibidores de pde10
PH12019502436A1 (en) 6-6 fused bicyclic heteroaryl compounds and their use as lats inhibitors
EA201590624A1 (ru) Циклические эфиры пиразол-4-ил-гетероциклил-карбоксамидных соединений и способы их применения
UA116644C2 (uk) Сполуки біариламіду як інгібітори кінази
AR084824A1 (es) Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
MX2019003248A (es) Mezclas fungicidas de pirazol.
NZ737725A (en) Crystalline forms of a bruton’s tyrosine kinase inhibitor
MY170520A (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
WO2013010946A3 (en) Pesticidal methods using substituted 3-pyridyl thiazole compounds and derivatives for combating animal pests i
EA201490807A1 (ru) Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1
MD4489C1 (ro) Derivaţi de 1,4-benzotiazepină, procedeu de sinteză a lor, compoziţii farmaceutice care le conţin şi utilizarea acestora pentru tratarea sau prevenirea afecţiunilor care implică modularea receptorilor de rianodină
RU2014121205A (ru) Производные азолов
WO2021250468A3 (en) Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5- methylphenyl)-v-[(ls)-2-cyclopropyl-l-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-v-prop-2-ynyl-l,3-thiazol-2-amine
RU2015103065A (ru) Кристаллическая форма i дималеата ингибитора тирозинкиназы и способ ее получения
MY167395A (en) Method for producing glufosinate p free acid
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
EP2970223A1 (en) Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
MX2014001604A (es) Compuestos de antranilamida y sus usos como plaguicidas.
CN112624988B (zh) 一种新的三氮唑化合物及其在农业中的应用